SCTB-41

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSCTB-41
Drug Alias NameSCTB41SCTB-41SCT-B41
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Anti-Vascular endothelial growth factorAnti-TGF-β
TargetsProgrammed cell death protein 1Vascular endothelial growth factorTransforming growth factor beta
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungDigestive System Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSinoCelltech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungDigestive System Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A